This database contains 24 studies, archived under the term: "apolipoproteins e"
Click here to filter this large number of results.
Effects of insulin and octreotide on memory and growth hormone in Alzheimer’s disease
Watson, G. Stennis,
Baker, Laura D.,
Cholerton, Brenna A.,
Rhoads, Kristoffer W.,
Merriam, George R.,
Schellenberg, Gerard D.,
Asthana, Sanjay,
Cherrier, Monique,
Craft, Suzanne
Both insulin alone and the somatostatin analogue octreotide alone facilitate memory in patients with Alzheimer’s disease (AD). Since octreotide inhibits endogenous insulin secretion, the cognitive effects of insulin and octreotide may not be independent. This study tested the individual and interactive effects of insulin and octreotide on memory and plasma growth hormone (GH) levels in […]
Effects of omega-3 fatty acids on inflammatory markers in cerebrospinal fluid and plasma in Alzheimer’s disease: the OmegAD study
Freund-Levi, Yvonne,
Hjorth, Erik,
Lindberg, Catharina,
Cederholm, Tommy,
Faxén-Irving, Gerd,
Vedin, Inger,
Palmblad, Jan,
Wahlund, Lars-Olof,
Schultzberg, Marianne,
Basun, Hans,
Eriksdotter-Jönhagen, Maria
Background: omega-3 fatty acids (omega-3 FAs) found in dietary fish or fish oils are anti-inflammatory agents that may influence Alzheimer’s disease (AD).; Objective: To study the effects of dietary omega-3 FA supplementation on inflammatory markers in cerebrospinal fluid (CSF) and plasma from patients with mild to moderate AD.; Methods: Thirty-five patients (70.3 +/- 8.2 years) […]
Effects of donepezil, galantamine and rivastigmine in 938 Italian patients with Alzheimer’s disease: a prospective, observational study
Santoro, Aurelia,
Siviero, Paola,
Minicuci, Nadia,
Bellavista, Elena,
Mishto, Michele,
Olivieri, Fabiola,
Marchegiani, Francesca,
Chiamenti, Andrea Maria,
Benussi, Luisa,
Ghidoni, Roberta,
Nacmias, Benedetta,
Bagnoli, Silvia,
Ginestroni, Andrea,
Scarpino, Osvaldo,
Feraco, Emidio,
Gianni, Walter,
Cruciani, Guido,
Paganelli, Roberto,
Di Iorio, Angelo,
Scognamiglio, Mario,
Grimaldi, Luigi Maria Edoardo,
Gabelli, Carlo,
Sorbi, Sandro,
Binetti, Giuliano,
Crepaldi, Gaetano,
Franceschi, Claudio
Acetylcholinesterase inhibitors (AChEIs) have been used to improve cognitive status and disability in patients with mild to moderate Alzheimer’s disease (AD). However, while the efficacy of AChEIs (i.e. how they act in randomized controlled trials) in this setting is widely accepted, their effectiveness (i.e. how they behave in the real world) remains controversial. To compare […]
Rosiglitazone monotherapy in mild-to-moderate Alzheimer’s disease: results from a randomized, double-blind, placebo-controlled phase III study
Gold, Michael,
Alderton, Claire,
Zvartau-Hind, Marina,
Egginton, Sally,
Saunders, Ann M.,
Irizarry, Michael,
Craft, Suzanne,
Landreth, Gary,
Linnamägi, Ulla,
Sawchak, Sharon
Background/aims: A phase II study of the peroxisome proliferator-activated receptor-γ agonist rosiglitazone extended release (RSG XR) in mild-to-moderate Alzheimer’s disease (AD) detected a treatment benefit to cognition in apolipoprotein E(APOE)-ε4-negative subjects. The current phase III study with prospective stratification by APOE genotype was conducted to confirm the efficacy and safety of RSG XR in mild-to-moderate […]
Neuroimaging predictors of brain amyloidosis in mild cognitive impairment
Objective: To identify a neuroimaging signature predictive of brain amyloidosis as a screening tool to identify individuals with mild cognitive impairment (MCI) that are most likely to have high levels of brain amyloidosis or to be amyloid-free.; Methods: The prediction model cohort included 62 MCI subjects screened with structural magnetic resonance imaging (MRI) and (11) […]
Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer’s disease
Salloway, Stephen,
Sperling, Reisa,
Fox, Nick C.,
Blennow, Kaj,
Klunk, William,
Raskind, Murray,
Sabbagh, Marwan,
Honig, Lawrence S.,
Porsteinsson, Anton P.,
Ferris, Steven,
Reichert, Marcel,
Ketter, Nzeera,
Nejadnik, Bijan,
Guenzler, Volkmar,
Miloslavsky, Maja,
Wang, Daniel,
Lu, Yuan,
Lull, Julia,
Tudor, Iulia Cristina,
Liu, Enchi,
Grundman, Michael,
Yuen, Eric,
Black, Ronald,
Brashear, H. Robert
Background: Bapineuzumab, a humanized anti-amyloid-beta monoclonal antibody, is in clinical development for the treatment of Alzheimer’s disease.; Methods: We conducted two double-blind, randomized, placebo-controlled, phase 3 trials involving patients with mild-to-moderate Alzheimer’s disease–one involving 1121 carriers of the apolipoprotein E (APOE) ε4 allele and the other involving 1331 noncarriers. Bapineuzumab or placebo, with doses varying […]
Plasma proteomics for the identification of Alzheimer disease
Less-invasive biomarkers for early Alzheimer disease (AD) are urgently needed. The present study aimed to establish a panel of plasma proteins that accurately distinguishes early AD from physiological aging and to compare the findings with previous reports. Fifty-eight healthy controls (CON) and 109 patients with AD dementia were randomly split into a training (40%) and […]